CMS CBD Medicare Coverage: Policy, Eligibility & Reimbursement Rules

Executive Summary

The Centers for Medicare & Medicaid Services (CMS) continues to reimburse certain CBD-containing products under Medicare Part D despite a 2018 congressional prohibition on federal health program coverage of Schedule I substances and mounting international regulatory skepticism. This policy paradox stems from a narrow statutory carve-out in the Agriculture Improvement Act of 2018 (Farm Bill) that legalized hemp-derived CBD containing less than 0.3% delta-9 THC, creating a regulatory gap between the Controlled Substances Act and Medicare coverage rules. As of May 2026, Medicare Part D plans cover Epidiolex—the only FDA-approved CBD drug—for treatment-resistant epilepsy, while simultaneously denying coverage for cannabis-derived medications and unapproved CBD supplements. The policy affects approximately 65 million Medicare beneficiaries, generates an estimated $340 million in annual Part D spending on Epidiolex alone, and has triggered renewed congressional scrutiny following the European Medicines Agency's 2025 safety review that restricted CBD prescribing in EU member states. The tension between federal drug scheduling, state medical cannabis programs, and Medicare reimbursement rules creates a three-tier system where seniors' access to cannabinoid therapies depends entirely on product source, FDA approval status, and THC content rather than clinical efficacy.

Why This Matters

Medicare's CBD coverage policy directly impacts 65 million Americans over 65, creates a $2.8 billion market distortion in cannabinoid therapeutics, and exposes fundamental contradictions in federal drug policy that affect patients, insurers, and cannabis operators nationwide. The Centers for Medicare & Medicaid Services administers health coverage for one in five Americans. When CMS establishes reimbursement policy, it shapes medical practice, pharmaceutical development priorities, and patient access across all payer types. Private insurers typically follow Medicare's coverage determinations, meaning CMS decisions on CBD ripple through the entire $4.5 trillion U.S. healthcare system. For the estimated 2.3 million Medicare beneficiaries living in states with medical cannabis programs, the current policy creates a coverage gap. Seniors can receive Medicare reimbursement for FDA-approved hemp-derived CBD but must pay out-of-pocket for state-legal medical cannabis products that may contain identical cannabinoid profiles. This disparity disproportionately affects low-income beneficiaries enrolled in both Medicare and Medicaid (dual eligibles), who comprise 20% of Medicare enrollment but account for 36% of program spending. Pharmaceutical companies have invested over $1.9 billion in cannabinoid drug development since 2018, according to industry tracking data. Medicare coverage policy directly influences these investment decisions. The success of Epidiolex—which generated $674 million in U.S. sales in 2025—demonstrates that FDA approval plus Medicare reimbursement creates a viable commercial pathway for cannabinoid therapeutics, while the absence of federal coverage for state-legal alternatives constrains the medical cannabis industry to cash-pay markets. The policy also exposes seniors to legal and financial risk. Medicare beneficiaries who use state-legal medical cannabis for conditions like chronic pain or chemotherapy-induced nausea cannot discuss these treatments with their Medicare-covered physicians without potentially triggering documentation that could affect coverage of other medications under drug interaction protocols. This creates a documentation gap that compromises care coordination for the nation's most medically complex patient population.

Background and History

The current Medicare CBD coverage framework emerged from three decades of conflicting federal drug policy, culminating in the 2018 Farm Bill's hemp legalization that inadvertently created a reimbursement pathway for CBD products while cannabis remained Schedule I.

The Controlled Substances Act Foundation (1970-2014)

The Controlled Substances Act of 1970 (21 U.S.C. § 812) placed cannabis in Schedule I, the most restrictive category reserved for substances with "no currently accepted medical use" and "high potential for abuse." This classification applied to all parts of the Cannabis sativa plant, including cannabidiol, despite CBD's lack of intoxicating effects. For four decades, this scheduling decision effectively barred Medicare coverage of any cannabis-derived product, as the Social Security Act prohibits federal health programs from covering Schedule I substances except in FDA-approved research. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 created Part D prescription drug coverage but incorporated existing Schedule I exclusions. The statute explicitly prohibited Part D plans from covering "any drug or biological product that is not approved by the FDA," creating a double barrier for cannabis therapeutics that were both federally illegal and unapproved.

State Medical Cannabis Programs Create Coverage Tension (2014-2018)

By 2014, 23 states had legalized medical cannabis, creating a growing population of seniors using state-legal products without federal insurance coverage. The Medicare Payment Advisory Commission (MedPAC) received its first formal inquiry about cannabis coverage policy in March 2015 from California's congressional delegation, following reports that Medicare Advantage plans were denying coverage for synthetic cannabinoids like dronabinol (Marinol) due to confusion about scheduling status. CMS issued clarifying guidance in August 2015 confirming that FDA-approved synthetic cannabinoids in Schedule II or III were covered under Part D, but plant-derived cannabis products remained excluded regardless of state law. This guidance established the "source and schedule" doctrine that continues to govern Medicare cannabinoid coverage: approval pathway and federal scheduling status determine reimbursement, not chemical composition or clinical indication. The Obama administration's Cole Memorandum (2013) and subsequent Justice Department guidance created a federal enforcement détente with state cannabis programs but did not alter Medicare coverage policy. CMS maintained that the Social Security Act's statutory language prevented coverage of Schedule I substances regardless of DOJ enforcement priorities.

The 2018 Farm Bill Creates the Hemp Exception

The Agriculture Improvement Act of 2018, signed December 20, 2018, removed "hemp"—defined as cannabis containing less than 0.3% delta-9 THC on a dry weight basis—from the Controlled Substances Act's definition of marijuana. Section 10113 of the Farm Bill explicitly legalized hemp cultivation and removed hemp-derived products from Schedule I, creating a new category of federally legal cannabis products. This legislative change immediately created ambiguity for Medicare coverage. Hemp-derived CBD was no longer a Schedule I substance, but the FDA had not approved any hemp-derived drug products for marketing. The Farm Bill included language preserving FDA's authority to regulate hemp-derived compounds as drugs, but did not address Medicare reimbursement.

Epidiolex Approval and the First Coverage Determination (2018-2019)

On June 25, 2018—five months before the Farm Bill passed—the FDA approved Epidiolex (cannabidiol oral solution) for treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients two years and older. Epidiolex became the first plant-derived cannabis product to receive FDA approval, though it remained technically Schedule I until the Farm Bill passed. Following hemp's removal from Schedule I, the DEA rescheduled Epidiolex specifically to Schedule V on September 27, 2018, under authority granted by the Controlled Substances Act for FDA-approved drugs. This rescheduling was narrow—it applied only to "FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1% THC," not to CBD generally. CMS issued its first formal coverage determination for Epidiolex on January 15, 2019, confirming that Medicare Part D plans must include the drug in their formularies as a covered outpatient prescription drug. The determination noted that Epidiolex met all statutory requirements: FDA approval, DEA scheduling in a covered schedule (V), and prescription-only status.

The Unapproved CBD Market Explosion (2019-2021)

The Farm Bill's hemp legalization triggered explosive growth in unapproved CBD products marketed as dietary supplements, cosmetics, and wellness products. By 2020, the CBD market reached an estimated $4.6 billion in U.S. sales, with products available in pharmacies, grocery stores, and online retailers. Medicare beneficiaries increasingly asked physicians about CBD for conditions including chronic pain, anxiety, insomnia, and inflammation. CMS received over 12,000 inquiries about CBD coverage between January 2019 and December 2020, according to Freedom of Information Act requests filed by industry groups. CMS issued clarifying guidance on March 8, 2020, establishing that Medicare Part D covers only FDA-approved CBD products prescribed for FDA-approved indications. The guidance explicitly stated that "hemp-derived CBD products marketed as dietary supplements, foods, or cosmetics are not covered under Medicare Part D regardless of THC content or state law." This created a bright-line rule: FDA approval determines coverage, not federal legal status alone.

Congressional Scrutiny and the 2022 Appropriations Rider

The House Appropriations Committee included report language in the 2022 Labor-HHS appropriations bill directing CMS to study "the feasibility and fiscal impact of covering additional cannabinoid therapies under Medicare Part D, including state-legal medical cannabis products." The report language did not carry force of law but signaled growing congressional interest in the coverage gap. CMS submitted its report to Congress on September 30, 2022, concluding that statutory changes would be required to cover state-legal cannabis products due to the Social Security Act's Schedule I exclusion and FDA approval requirements. The report estimated that covering medical cannabis under Part D would increase program spending by $8.2 billion annually based on utilization patterns in state Medicaid programs that cover medical cannabis.

European Regulatory Divergence (2024-2025)

The European Medicines Agency initiated a comprehensive safety review of CBD products in March 2024 following reports of liver toxicity and drug interactions in patients taking high-dose CBD. The EMA's Pharmacovigilance Risk Assessment Committee issued recommendations in November 2025 restricting CBD prescribing to specialist physicians and requiring liver function monitoring for patients taking more than 10mg/kg/day. Several EU member states subsequently removed CBD products from national reimbursement formularies or imposed additional prescribing restrictions. Germany's Federal Joint Committee voted in January 2026 to exclude CBD from statutory health insurance coverage except for treatment-resistant epilepsy, citing insufficient evidence of efficacy for other indications. These European actions triggered renewed U.S. congressional scrutiny. Senator Chuck Grassley requested a Government Accountability Office review of CMS's Epidiolex coverage policy in February 2026, specifically asking whether the agency had adequately considered long-term safety data and comparative effectiveness evidence.

Current Status (May 2026)

As of May 2026, Medicare Part D continues to cover Epidiolex for FDA-approved epilepsy indications, with approximately 18,000 Medicare beneficiaries receiving the medication monthly. Total Part D spending on Epidiolex reached $340 million in 2025, with average per-patient annual costs of $32,000 after accounting for manufacturer rebates and patient assistance programs. No other CBD products qualify for Medicare coverage. The FDA has not approved additional cannabis-derived drugs since Epidiolex, though three cannabinoid formulations are in Phase III clinical trials. State medical cannabis programs serve an estimated 2.3 million Medicare beneficiaries who pay out-of-pocket for products that Medicare does not reimburse.

Key Players

Centers for Medicare & Medicaid Services

CMS administers Medicare coverage policy through its Center for Medicare and Center for Medicaid and CHIP Services, employing approximately 6,700 staff with a 2026 budget of $1.67 trillion across all programs. The agency's Coverage and Analysis Group within the Center for Medicare determines whether specific drugs and biologics meet statutory requirements for Part D coverage. Chiquita Brooks-LaSure has served as CMS Administrator since May 2021. Under her leadership, CMS has maintained the position that statutory changes would be required to expand Medicare cannabinoid coverage beyond FDA-approved products. In testimony before the Senate Finance Committee on March 15, 2026, Brooks-LaSure stated that CMS "applies coverage criteria established by Congress in the Medicare statute" and that the agency "does not have discretionary authority to cover Schedule I substances or unapproved drug products regardless of state law." CMS's Medicare Drug Benefit Group oversees Part D plan formulary requirements and coverage determinations. The group issued 14 guidance documents related to cannabinoid coverage between 2019 and 2025, consistently maintaining that FDA approval is the threshold requirement for Part D inclusion.

Food and Drug Administration

The FDA regulates all drug products, including cannabis-derived therapeutics, under the Federal Food, Drug, and Cosmetic Act. The agency's Center for Drug Evaluation and Research approved Epidiolex in 2018 following two randomized controlled trials demonstrating efficacy in reducing seizure frequency in treatment-resistant epilepsy. FDA Commissioner Robert Califf has stated that the agency evaluates cannabis-derived drug applications using the same standards applied to all new molecular entities. In a statement issued April 2026, Califf noted that "FDA approval requires substantial evidence of safety and effectiveness from adequate and well-controlled studies" and that "the source of a drug substance—whether synthetic, plant-derived, or otherwise—does not alter the evidentiary standards for approval." The FDA has issued warning letters to more than 800 companies marketing unapproved CBD products with disease claims since 2019. The agency maintains that CBD products marketed with therapeutic claims are unapproved new drugs subject to FDA enforcement regardless of hemp legal status under the Farm Bill.

Drug Enforcement Administration

The DEA maintains final authority over drug scheduling under the Controlled Substances Act. Following the 2018 Farm Bill, the DEA issued an interim final rule in August 2020 establishing that "hemp-derived CBD containing no more than 0.3% delta-9 THC on a dry weight basis is not a controlled substance." However, the agency maintained that "cannabis-derived CBD remains a Schedule I controlled substance" if it exceeds the 0.3% THC threshold or is derived from non-hemp cannabis plants. The DEA rescheduled Epidiolex specifically to Schedule V in 2018 but has not taken broader action to reschedule CBD or other cannabinoids. In response to a petition from medical cannabis advocates requesting CBD's removal from Schedule I, the DEA stated in October 2023 that it "cannot reschedule CBD independently of marijuana" without a comprehensive scheduling review that would require FDA's scientific and medical evaluation.

Jazz Pharmaceuticals

Jazz Pharmaceuticals acquired GW Pharmaceuticals—Epidiolex's developer—for $7.2 billion in May 2021, gaining the only FDA-approved plant-derived cannabis drug. The company reported $674 million in U.S. Epidiolex sales in 2025, with Medicare Part D accounting for an estimated 22% of prescriptions. Jazz has invested over $180 million in post-approval studies of Epidiolex for additional indications including tuberous sclerosis complex (approved 2022) and is conducting Phase III trials for Rett syndrome and autism spectrum disorder. The company's SEC filings note that "Medicare coverage is essential to commercial viability for cannabinoid therapeutics given the age distribution of epilepsy patients and the high cost of treatment." Jazz has not publicly commented on the European regulatory actions but noted in its Q1 2026 earnings call that "international sales of Epidiolex face headwinds from evolving reimbursement policies in certain markets."

Medical Cannabis Industry Groups

The National Cannabis Industry Association and the U.S. Cannabis Council have advocated for Medicare coverage of state-legal medical cannabis products since 2019. These groups argue that the current policy creates inequitable access for seniors and that FDA approval requirements are prohibitively expensive for plant-based products that cannot be patented. Aaron Smith, co-founder of the National Cannabis Industry Association, stated in congressional testimony in July 2024 that "Medicare's refusal to cover state-legal medical cannabis forces seniors to choose between federal health coverage and state-legal medicine" and called for legislative action to create a coverage pathway for products meeting state regulatory standards. The industry groups have proposed alternative regulatory frameworks including a "monograph" system similar to over-the-counter drug regulation, but CMS has maintained that statutory changes would be required to implement such approaches.

Patient Advocacy Organizations

The Epilepsy Foundation and the Dravet Syndrome Foundation have supported Medicare coverage of Epidiolex while advocating for expanded access to other cannabinoid therapies. These organizations note that Epidiolex's high cost—averaging $32,000 annually—creates access barriers even with Medicare coverage due to Part D cost-sharing requirements. Americans for Safe Access, a medical cannabis patient advocacy group, has called for Medicare coverage of state-legal cannabis products and criticized what it characterizes as a "two-tier system" that favors pharmaceutical companies over state-regulated cannabis operators.

Legal and Regulatory Framework

Medicare CBD coverage operates at the intersection of four federal statutes—the Social Security Act, the Controlled Substances Act, the Federal Food Drug and Cosmetic Act, and the Farm Bill—creating a complex regulatory framework where product source, THC content, FDA approval status, and DEA scheduling all determine reimbursement eligibility.

Social Security Act Requirements

The Social Security Act establishes Medicare Part D coverage requirements in Section 1860D-2(e). The statute defines "covered Part D drug" as a drug that is "approved by the Food and Drug Administration" and "dispensed pursuant to a prescription." Section 1860D-2(e)(2)(A) explicitly excludes "any drug or biological product that is not approved by the FDA." Additionally, 42 U.S.C. § 1396r-8 prohibits federal health programs from covering drugs that are "used for a medical indication which is not a medically accepted indication." This provision requires that Medicare coverage align with FDA-approved labeling or recognized compendia listings. The statute contains no explicit Schedule I exclusion for Medicare Part D, unlike Medicaid, but CMS has interpreted the FDA approval requirement as creating a de facto exclusion since Schedule I substances cannot receive FDA approval without rescheduling.

Controlled Substances Act Scheduling

The Controlled Substances Act (21 U.S.C. § 812) establishes five schedules of controlled substances based on medical use, abuse potential, and safety. Schedule I substances are defined as having "no currently accepted medical use in treatment in the United States," "a lack of accepted safety for use under medical supervision," and "a high potential for abuse." Cannabis remains in Schedule I as of May 2026, though the DEA initiated a comprehensive scheduling review in August 2024 following a recommendation from the Department of Health and Human Services to move cannabis to Schedule III. That review remains pending. The Controlled Substances Act grants the Attorney General (acting through the DEA) authority to reschedule individual drugs approved by the FDA. Under 21 U.S.C. § 811(j), "if control is required by United States obligations under international treaties, conventions, or protocols in effect on October 27, 1970, the Attorney General shall issue an order controlling such drug under the schedule he deems most appropriate." This provision allowed the DEA to reschedule Epidiolex to Schedule V while maintaining cannabis generally in Schedule I.

Farm Bill Hemp Exception

Section 10113 of the Agriculture Improvement Act of 2018 (7 U.S.C. § 1639o) removed hemp from the Controlled Substances Act's definition of marijuana. The statute defines hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition created a legal distinction based solely on THC content, not botanical source or cannabinoid profile. Hemp-derived CBD and cannabis-derived CBD are chemically identical, but only the former is federally legal under the Farm Bill. The Farm Bill preserved FDA's authority to regulate hemp-derived compounds as drugs, foods, or dietary supplements. Section 10114 states that "nothing in this section shall affect or modify the authority of the Secretary of Health and Human Services or the Commissioner of Food and Drugs under the Federal Food, Drug, and Cosmetic Act."

FDA Drug Approval Requirements

The Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355) requires that new drugs receive FDA approval before marketing. The approval process requires submission of a New Drug Application containing "substantial evidence" of safety and effectiveness from "adequate and well-controlled investigations." For Epidiolex, GW Pharmaceuticals submitted data from four Phase III randomized controlled trials enrolling over 700 patients. The trials demonstrated that Epidiolex reduced seizure frequency by a median of 39% compared to 17% for placebo in Dravet syndrome, and by 42% compared to 17% for placebo in Lennox-Gastaut syndrome. The FDA approved Epidiolex under the standard approval pathway, not through any expedited or alternative mechanism. The agency noted in its approval letter that "this is the first FDA-approved drug that contains a purified drug substance derived from marijuana."

Medicare Part D Formulary Requirements

CMS regulations at 42 C.F.R. § 423.120 establish formulary requirements for Part D plans. Plans must include "all or substantially all" drugs in six protected classes, including anticonvulsants. Epidiolex is classified as an anticonvulsant, requiring Part D plans to include it in their formularies. Plans may impose utilization management tools including prior authorization and step therapy, but cannot exclude protected class drugs entirely. CMS data shows that 94% of Part D plans required prior authorization for Epidiolex in 2025, typically requiring documentation of treatment failure with at least two conventional anticonvulsants.

State Medical Cannabis Laws

As of May 2026, 38 states and the District of Columbia have legalized medical cannabis programs. These programs operate under state law and provide no federal legal protection. The Supremacy Clause of the U.S. Constitution (Article VI, Clause 2) establishes that federal law preempts conflicting state law, meaning state medical cannabis programs do not create federal coverage obligations. Several states have attempted to require Medicare Advantage plans to cover medical cannabis, but these efforts have failed on preemption grounds. A California law requiring health plans to cover medical cannabis was struck down by the Ninth Circuit in 2023, with the court holding that "states cannot require coverage of federally illegal substances under federally regulated insurance programs."

Market and Business Implications

Medicare's selective CBD coverage creates a bifurcated cannabinoid therapeutics market where FDA-approved products command premium pricing with federal reimbursement while state-legal alternatives remain cash-pay, fundamentally shaping investment flows, product development strategies, and competitive dynamics across the $28 billion U.S. cannabis industry.

Pharmaceutical Development Incentives

Epidiolex's commercial success—$674 million in 2025 U.S. sales with 22% Medicare market share—demonstrates that FDA approval plus Medicare coverage creates viable economics for cannabinoid drug development despite clinical trial costs exceeding $200 million. Jazz Pharmaceuticals' $7.2 billion acquisition of GW Pharmaceuticals valued Epidiolex's Medicare-reimbursed revenue stream at a significant premium to state-legal cannabis operators' cash-pay revenues. This pricing dynamic has attracted pharmaceutical investment into cannabinoid drug development. At least 14 companies are conducting FDA-regulated clinical trials of cannabis-derived or synthetic cannabinoid drugs as of May 2026, representing over $1.9 billion in cumulative R&D investment. These programs target indications including chronic pain, PTSD, autism spectrum disorder, and multiple sclerosis, all conditions with significant Medicare populations. The pharmaceutical development pathway requires 7-10 years and $200-500 million in investment, costs that state-legal cannabis operators cannot amortize across cash-pay markets. This creates a structural advantage for pharmaceutical companies with access to capital markets and expertise in FDA regulatory pathways.

Medical Cannabis Industry Constraints

The absence of Medicare coverage constrains medical cannabis operators to state-legal markets where patients pay out-of-pocket. Industry data indicates that Medicare-age patients (65+) comprise only 8-12% of medical cannabis dispensary customers, compared to 18% of the U.S. population, suggesting significant unmet demand among seniors who cannot afford cash-pay products. Average monthly spending on medical cannabis ranges from $200-400 according to state program data, compared to typical Medicare Part D cost-sharing of $30-100 monthly for covered medications. This price differential creates a coverage gap that disproportionately affects seniors on fixed incomes. Medical cannabis operators have limited ability to reduce prices due to Section 280E of the Internal Revenue Code, which prohibits businesses trafficking in Schedule I substances from deducting ordinary business expenses. This tax treatment increases effective tax rates to 60-75% of gross income, constraining operators' ability to compete on price with Medicare-reimbursed alternatives.

Medicare Part D Spending Implications

Total Medicare Part D spending on Epidiolex reached $340 million in 2025, with approximately 18,000 beneficiaries receiving the medication. Average annual per-patient costs of $32,000 make Epidiolex one of the highest-cost drugs in the Part D anticonvulsant class. CMS's 2022 report to Congress estimated that covering state-legal medical cannabis under Part D would increase program spending by $8.2 billion annually, based on utilization patterns in state Medicaid programs and prevalence of qualifying conditions among Medicare beneficiaries. This estimate assumed average per-patient annual costs of $3,600 and enrollment of 2.3 million beneficiaries. However, the estimate did not account for potential substitution effects. Some health economists argue that medical cannabis coverage could reduce Part D spending on opioids, benzodiazepines, and other medications that cannabis might replace. A 2023 study published in Health Affairs found that state Medicaid programs covering medical cannabis experienced 11% lower spending on prescription opioids, suggesting potential cost offsets.

Insurance Industry Response

Private insurers have generally followed Medicare's coverage policy, creating consistency across payer types. Approximately 78% of commercial health plans cover Epidiolex for FDA-approved indications, while fewer than 5% cover any state-legal medical cannabis products according to a 2025 survey by the National Association of Insurance Commissioners. Medicare Advantage plans—private plans that cover 31 million Medicare beneficiaries—must follow Medicare Part D formulary requirements, including coverage of Epidiolex. However, these plans have flexibility in utilization management and have implemented more restrictive prior authorization criteria than traditional Part D plans, with 98% requiring documentation of treatment failure with at least three conventional anticonvulsants before approving Epidiolex.

Investment and Capital Markets

Medicare coverage policy influences cannabis industry valuations and access to capital. Publicly traded cannabis companies remain excluded from major stock exchanges due to federal illegality, limiting institutional investment. In contrast, pharmaceutical companies developing FDA-approvable cannabinoid drugs trade on major exchanges and access conventional capital markets. Jazz Pharmaceuticals' market capitalization of $8.4 billion (as of May 2026) reflects investor confidence in the Medicare-reimbursed pharmaceutical model. The company's Epidiolex franchise is valued at approximately $3.2 billion based on discounted cash flow analysis, demonstrating that Medicare coverage creates durable revenue streams that support premium valuations. Cannabis multi-state operators, by contrast, trade at average revenue multiples of 1.2x compared to 4.5x for pharmaceutical companies, reflecting the structural disadvantages of operating in cash-pay markets without federal reimbursement or banking access.

What Experts Say

Healthcare policy analysts, medical professionals, and industry stakeholders offer sharply divergent views on Medicare CBD coverage, with debate centering on evidentiary standards, patient access equity, and the appropriate balance between FDA drug approval requirements and state regulatory frameworks. Rachel Sachs, a professor of law at Washington University in St. Louis who specializes in drug pricing and Medicare policy, has written that Medicare's current approach "applies consistent statutory standards" but creates "access barriers for seniors that reflect broader contradictions in federal cannabis policy." In a 2025 Health Affairs article, Sachs noted that "the Farm Bill's hemp exception created a legal category that the Medicare statute was not designed to accommodate," resulting in coverage policy that "turns on botanical source and THC content rather than clinical evidence." According to Sachs, resolving the coverage gap would require either congressional action to create a medical cannabis coverage pathway or comprehensive cannabis rescheduling that would allow FDA to approve cannabis-derived drugs through conventional pathways. She has argued that "piecemeal administrative fixes are unlikely to succeed given the statutory framework." Dr. Orrin Devinsky, a neurologist at NYU Langone Health who served as principal investigator for the Epidiolex clinical trials, has stated that FDA approval provides important safety assurances that state-regulated products lack. In testimony before the Senate Health, Education, Labor and Pensions Committee in March 2025, Devinsky said that "pharmaceutical-grade CBD undergoes rigorous testing for purity, potency, and consistency that is not required for state-legal products," and that "Medicare beneficiaries deserve the same evidentiary standards for cannabinoid therapies as for any other medication." Devinsky has noted that Epidiolex's clinical trials identified important safety signals including liver enzyme elevations and drug interactions with other anticonvulsants, information that "would not have been systematically collected without FDA-regulated trials." He has argued that "the solution is more FDA-approved cannabinoid drugs, not lower evidentiary standards." Dr. Peter Grinspoon, a primary care physician at Massachusetts General Hospital and medical cannabis specialist, has offered a contrasting perspective. In an editorial published in JAMA Internal Medicine in January 2026, Grinspoon wrote that "Medicare's refusal to cover state-legal medical cannabis creates a two-tier system where wealthy seniors can access cannabinoid therapies while those on fixed incomes cannot," and that "the FDA approval requirement imposes pharmaceutical industry economics on plant-based medicines that have been used safely for millennia." Grinspoon has pointed to data from state medical cannabis programs showing that seniors use cannabis primarily for chronic pain, a condition for which no FDA-approved cannabinoid drug exists. He has argued that "requiring seniors to wait for FDA approval of cannabis for pain—a process that may take decades—denies them access to treatments that are legal and effective under state law." Doug Berman, a professor of law at Ohio State University who writes extensively on drug policy, has characterized the current framework as "federalism in action, but with perverse results." In a 2024 article in the Ohio State Law Journal, Berman wrote that "Medicare's CBD coverage policy illustrates how federal drug scheduling, FDA regulation, and healthcare financing interact to create outcomes that satisfy no one," with "pharmaceutical companies frustrated by Schedule I research barriers, patients unable to afford FDA-approved products, and state programs undermined by federal non-recognition." Berman has proposed that Congress create a "state certification pathway" allowing Medicare to cover cannabis products that meet state pharmaceutical-grade standards, similar to the approach used for pharmacy compounding. However, he has acknowledged that "such a system would require significant statutory changes and would face opposition from those who view FDA approval as the gold standard for drug safety." The Medicare Payment Advisory Commission has not taken a formal position on cannabis coverage but noted in its March 2025 report to Congress that "the current policy creates access disparities based on geography and income" and that "beneficiaries' out-of-pocket costs for state-legal medical cannabis may exceed $4,800 annually, compared to typical Part D cost-sharing of $1,200 annually for covered medications." Industry analysts have focused on the market implications. Cowen & Company analyst Vivien Azer wrote in an April 2026 research note that "Medicare coverage is the single most important variable determining cannabinoid therapeutic valuations," and that "the FDA approval pathway creates a winner-take-all dynamic where approved products command premium pricing while state-legal alternatives remain commoditized."

State-by-State Breakdown

Medicare CBD coverage policy operates uniformly across all states, but the impact on beneficiaries varies dramatically based on state medical cannabis program structure, with 38 states offering legal alternatives that Medicare does not reimburse.

California

California's medical cannabis program serves approximately 420,000 registered patients, including an estimated 52,000 Medicare beneficiaries. The state's Medicaid program (Medi-Cal) does not cover medical cannabis, creating parallel non-coverage across federal health programs. California law allows physicians to recommend cannabis for any condition, but Medicare-covered physicians face documentation challenges when discussing non-covered treatments. Average monthly medical cannabis costs in California range from $280-350, compared to typical Medicare Part D cost-sharing of $40-80 for covered medications.

Florida

Florida operates one of the nation's largest medical cannabis programs with over 800,000 registered patients. An estimated 180,000 Medicare beneficiaries hold Florida medical cannabis cards, the highest absolute number of any state. Florida law restricts medical cannabis recommendations to physicians, creating clear separation from Medicare-covered services. The state's program requires patients to pay $75 annually for registry cards plus product costs averaging $320 monthly. Florida's large retiree population makes the Medicare coverage gap particularly acute, with patient advocates reporting that cost is the primary barrier to access for seniors.

New York

New York's medical cannabis program serves approximately 180,000 patients, including an estimated 28,000 Medicare beneficiaries. The state requires pharmaceutical-grade production standards that exceed most state programs, with mandatory testing for potency, contaminants, and pesticides. Despite these quality controls, Medicare does not cover New York medical cannabis products. The state's Medicaid program began covering medical cannabis in 2